1

Topic 01 – Coronary heart disease

January 14th, Thursday 2010

001

Predictive Value of Post Treatment Platelet Reactivity for Occurrence of Post-discharge Bleeding After Non ST Elevation Acute Coronary Syndrome

Thomas Cuisset (1), Corinne Frere (2), Jacques Quilici (3), Laurent Bali (3), Raphael Poyet (4), Pierre E Morange (2), Marie Christine Alessi (2), Jean Louis Bonnet (3)

(1) CHU Timone, Service de Cardiologie Interventionnelle, Marseille, France – (2) Inserm, U626, Faculté de Médecine Timone, Laboratory of Haematology, Marseille, France – (3) CHU Timone, Department of Cardiology, Marseille, France – (4) Inserm, U626, Faculté de Médecine, Laboratoire d'Hématologie, Marseille, France

Aims: We assessed prospectively the association between occurrence of post-discharge non–CABG-related TIMI major and minor bleedings and post treatment platelet reactivity in patients with Non ST Elevation Acute Coronary Syndrome (NSTE ACS).

Methods and Results: 597 consecutive patients admitted with NSTE ACS were prospectively included. Between hospital discharge and one month follow-up, we observed 16 (2.7%) non–CABG-related TIMI hemorhagic complications including 5 (0.84%) major and 11 (1.8%) minor bleeds. Patients with bleeding had significantly lower post treatment values of ADP-induced aggregation ($43\pm14\%$ versus $56\pm19\%$, P=0.002) and platelet reactivity index VASP ($43\pm14\%$ versus $54\pm23\%$; P=0.04) and a trend for lower values of arachidonic acid-induced aggregation (2.4 ± 5.4 versus 13 ± 21 ; P=0.27). After stratification by quartiles based on post treatment ADP-induced platelet aggregation, we identified patients in the first quartile as hyper-responders with very low post treatment platelet reactivity, below <40%. The risk of TIMI major and minor bleeding was significantly higher in the first quartile of hyper-responders than in the others quartiles: 10 (6.6%) versus 6 (1.4%), p=0.001.

Conclusion: Our results suggest that assessment of post treatment platelet reactivity might be used to detect hyper responders to antiplatelet therapy with higher risk of non-CABG related bleedings and tailor antiplatelet therapy according to both ischemic and bleeding risk.

002

Implementation of the ESC guidelines on the management of AMI in community hospitals

Jean Ferrières (1), Jean-Bernard Ruidavets (2), Dominique Arveiler (3), Jean Dallongeville (4), Bernadette Haas (5), Michèle Montaye (6), Annie Bingham (7), Vanina Bongard (2), Pierre Ducimetière (8)

(1) CHU Rangueil, Service de Cardiologie B, Toulouse Cedex 9, France – (2) CHU, University School of Medicine, Epidemiology, INSERM U558, Toulouse, France – (3) Strasbourg University School of Medicine, Epidemiology and Public Health, Strasbourg, France – (4) INSERM U744, Institut Pasteur, Lille, France – (5) Faculté de Médecine, Laboratoire d'Epidémiologie et de Santé Publique, Strasbourg Cedex, France – (6) INSERM U744, Unité d'Epidémiologie et de Santé Publique, Lille Cedex, France – (7) INSERM U909, Paul Brousse Hospital, Villejuif, France – (8) IFR69, Paul Brousse Hospital, Villejuif, France

Background: Discrepancies may exist between guidelines and their implementation in daily practice. The aim of this study was to analyze management of acute myocardial infarction (AMI) in three population registries.

Methods: In three areas of France, we registered in 2006 all acute coronary syndromes (ACS) aged 35-74 years, without any previous history of coronary heart disease, in the 3 MONICA Registries of Lille, Strasbourg and Toulouse. We obtained data before, during and after hospitalization for all consecutive

cases of ACS in all hospitals covered by the 3 registries. In order to compare with the 2008 ESC guidelines on AMI, we restricted our analysis in patients (pts) with a discharge diagnosis of incident AMI.

Results: Among 2018 incident ACS hospitalized in 2006, 1212 (60%) were discharged with a diagnosis of incident AMI (mean age 57.2 \pm 10.3, 79.2% men). The delay between symptom onset and first medical contact was <1 h in 25%, <2 h in 45% and <4 h in 59% of pts. The first medical contact was a physician-manned ambulance for 48% of pts. The delay between symptom onset and hospitalization was <1 h in 8%, <2 h in 26% and <4 h in 53% of pts. The delay between symptom onset and hospitalization was <1 h in 8%, <2 h in 26% and <4 h in 53% of pts. The delay between symptom onset and hospitalization was <1 h in 8%, <2 h in 26% and <4 h in 53% of pts. Pre-hospital care included pre-hospital fibrinolysis in 10.6%, aspirin in 35.5% and clopidogrel in 15.1% of pts. Among all AMI, 74% were hospitalized in a percutaneous coronary intervention (PCI)-capable hospital and 53% had a primary angioplasty. During the first 24 h of hospitalization, 60.7% had PCI, 5.0% in-hospital fibrinolysis, 89.2% aspirin, 86.2% clopidogrel, 66.0% β -blockers, 60.7% angiotensin-converting enzyme (ACE) inhibitors and 42.2% statins. Among discharged pts, 93.7% had aspirin, 86.3% clopidogrel, 87.0% β -blockers, 75.6% ACE inhibitors and 90.8% had statins. One month mortality was 6.0%.

Conclusion: The management of AMI has greatly improved in France. However, the first medical contact often remains a general practitioner and about half of the pts are admitted at hospital more than 4 hours after symptom onset.

003

Comparison of Visual Scoring and Quantitative Planimetry Methods for Estimation of Global Infarct Size on Delayed Enhanced Cardiac MRI and Validation with Myocardial Enzymes

Nathan Mewton, Eric Bonnefoy, Michel Ovize, Didier Revel, Pierre Croisille

Hopital Cardiovasculaire Louis Pradel, Cardiologie, Bron, France

Objective: Although delayed enhanced CMR has become a reference method for infarct size quantification, there is no ideal method to quantify total infarct size in a routine clinical practice. In a prospective study we compared the performance and post-processing time of a global visual scoring method to standard quantitative planimetry and we compared both methods to the peak values of myocardial biomarkers.

Material and Methods: This study had local ethics committee approval; all patients gave written informed consent. 136 patients admitted with reperfused AMI to our intensive care unit had a complete CMR study with Gadolinium-contrast injection 4 ± 2 days after admission. A global visual score was defined on a 17-segment model and compared with the quntitative planimetric evaluation of hyperenhancement. The peak values of serum troponin I (TnI) and creatine kinase (CK) release were measured in each patient.

Results: The mean percentage of hyperenhanced myocardium determined by the quantitative planimetry method was (21.3 ± 14.1) with a range of 0-68,6%. There was an excellent correlation between quantitative planimetry and visual global scoring for the hyperenhancement extent's measurement (r=0.91; y=1.04x+3,2; SEE=1.2; P<0.001) The Bland-Altman plot showed a good concordance between the two approaches (mean of the differences = -4.04% with a standard deviation of 6.9).

Mean post-processing time for quantitative planimetry was significantly longer than visual scoring post-processing time (23.7 ± 5.7 minutes VS 5.0 \pm 1.1 minutes respectively, P<0.001). Correlation between peak CK and quantitative planimetry was r=0.71 (P<0.001) and r=0.75 (P<0.001) with visual global scoring. Correlation between peak troponin I and quantitative planimetry was r= 0.69 (P<0.001) and r= 0.70 (P<0.001) with visual global scoring.

Conclusion: A visual approach based on a 17-segment model allows a rapid and accurate assessment of the myocardial global delayed enhancement. This scoring method could be used on a daily practice and useful for the management strategy of post-MI patients.